Semaglutide Buy Research Grade — USA
Research Use Only: All compounds supplied by Aarise Healthcare are strictly for laboratory research and scientific investigation. Not intended for human consumption, therapeutic use, or clinical application. All purchases must comply with applicable local laws and regulations.
Aarise Healthcare exports Semaglutide (CAS: 910463-68-6) to research institutions in USA. Our WHO-GMP certified facility in India supplies 98%+ purity Semaglutide for GLP-1 receptor agonism and metabolic research.
Semaglutide Export Specifications for USA
| Compound | Semaglutide |
| CAS Number | 910463-68-6 |
| Purity | 98%+ (HPLC verified) |
| Form | Lyophilised powder |
| Regulatory Reference | FDA |
| Shipping | DHL/FedEx temperature-controlled |
| Transit to USA | 5-10 business days |
| Documentation | CoA, HPLC, MS, export docs |
Research Applications of Semaglutide
Semaglutide is used in GLP-1 receptor agonism and metabolic research. Research institutions in USA source this compound for preclinical studies under applicable FDA research regulations.
Why USA Researchers Source Semaglutide from India
- WHO-GMP certified Indian manufacturer — internationally recognised compliance
- Competitive pricing for bulk research quantities
- Full export documentation package for FDA compliance
- Temperature-controlled DHL/FedEx shipping to USA
- Dedicated international research supply team
- 98%+ purity guaranteed with independent third-party CoA
Related Peptides in USA
Tirzepatide in USA | Retatrutide in USA | Liraglutide in USA | Mazdutide in USA
Semaglutide — Other Countries
Semaglutide in UK | Semaglutide in Germany | Semaglutide in Australia | Semaglutide in Canada
Source from India — Key Manufacturing Cities
Semaglutide in Mumbai, India | Semaglutide in Delhi, India | Semaglutide in Hyderabad, India | Semaglutide in Bangalore, India
Request Semaglutide for your USA research facility: Send your institution details and quantity requirements. We respond within 24 hours with FOB pricing and export documentation.




